Akhmadu Muradi

Dr. Akhmadu Muradi

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2012 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
TOTakuya Okada
Takuya Okada
MYMasato Yamaguchi
Masato Yamaguchi
AMAkhmadu Muradi
Akhmadu Muradi
YNYoshikatsu Nomura
Yoshikatsu Nomura
KUKensuke Uotani
Kensuke Uotani
KSKoji Sugimoto
Koji Sugimoto

11 July 2013 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
AMAkhmadu Muradi
Akhmadu Muradi
MYMasato Yamaguchi
Masato Yamaguchi
TOTakuya Okada
Takuya Okada
YNYoshikatsu Nomura
Yoshikatsu Nomura
KIKoji Idoguchi
Koji Idoguchi
KSKoji Sugimoto
Koji Sugimoto

20 September 2022 in Life
Verified
Journal Article
Open access
PDF file
AMAkhmadu Muradi
Akhmadu Muradi
CJChyntia Olivia Maurine Jasirwan
Chyntia Olivia Maurine Jasirwan
CSCharley Simanjuntak
Charley Simanjuntak
DPDedy Pratama
Dedy Pratama
RSRaden Suhartono
Raden Suhartono
AKAria Kekalih
Aria Kekalih
Diabetes mellitus (DM) is a significant risk factor for peripheral arterial disease (PAD). PAD affects 20% of DM patients over 40 and has increased by 29% in the last 50 years. The gut microbiota produces short-chain fatty acids (SCFAs) that affect atherosclerosis. SCFA inhibits inflammation, which contributes to atherosclerosis. This study tried to link feces SCFA levels to atherosclerosis in people with diabetes with peripheral arterial disease (PAD). The study included 53 people with diabetes and PAD: gas chromatography-mass spectrometry measured acetate, butyrate, and propionate levels in feces samples (GC-MS). There was a positive correlation between random blood glucose (RBG) levels, peak systolic velocity (PSV), volume flow (VF), plaque, relative and absolute acetate, relative valerate, butyrate, and propionate. This supports the idea that elevated SCFA levels in type 2 diabetic (T2D) patients reduce adipose tissue inflammation and cholesterol metabolism, contributing to atherosclerosis pathogenesis. We conclude that increased fecal SCFA excretion is linked to cardiovascular disease. To determine the causal effect correlation of the SCFA with clinical and laboratory parameters for PAD in DM patients, compare the SCFA in plasma and feces, and account for confounding variables, a specific method with larger sample sizes and more extended follow-up periods is required.

9 February 2023 in Livers
Verified
Journal Article
Open access
PDF file
CJChyntia Olivia Maurine Jasirwan
Chyntia Olivia Maurine Jasirwan
AMAkhmadu Muradi
Akhmadu Muradi
RARadiana Dhewayani Antarianto
Radiana Dhewayani Antarianto
Whether acute or chronic, liver failure is a state of liver dysfunction that can progress to multiorgan failure. Mortality in liver failure patients is approximately 80–90% and is caused by detoxification failure, which triggers other immediate complications, such as encephalopathy, coagulopathy, jaundice, cholestasis, and acute kidney failure. The ideal treatment for liver failure is liver transplantation, but the long waiting period for the right donor match causes unavoidable deaths in most patients. Therefore, new therapies, such as tissue engineering, hepatocyte transplantation, and stem cells, are now being studied to anticipate the patient’s condition while waiting for liver transplantation. This literature review investigated the effectiveness of some bio-artificial liver support systems using review methods systematically from international publication sites, including PubMed, using keywords, such as bio-artificial liver, acute and chronic liver failure, extracorporeal liver support system (ECLS), MARS, single-pass albumin dialysis (SPAD). Artificial and bioartificial liver systems can show specific detoxification abilities and pathophysiological improvements in liver failure patients but cannot reach the ideal criteria for actual liver function. The liver support system must provide the metabolic and synthetic function as in the actual liver while reducing the pathophysiological changes in liver failure. Aspects of safety, cost efficiency, and practicality are also considered. Identifying the technology to produce high-quality hepatocytes on a big scale is essential as a medium to replace failing liver cells. An increase in detoxification capacity and therapeutic effectiveness must also focus on patient survival and the ability to perform liver transplantation.

1 January 2012 in Diagnostic and Interventional Radiology
Verified
Journal Article
Closed access
AMAkhmadu Muradi
Akhmadu Muradi
MYMasato Yamaguchi
Masato Yamaguchi
AKAtsushi Kitagawa
Atsushi Kitagawa
YNYoshikatsu Nomura
Yoshikatsu Nomura
TOTakuya Okada
Takuya Okada
KSKoji Sugimoto
Koji Sugimoto
Diagnostic and Interventional Radiology

1 July 2015 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
YNYoshikatsu Nomura
Yoshikatsu Nomura
KSK. Sugimoto
K. Sugimoto
YGY. Gotake
Y. Gotake
KYK. Yamanaka
K. Yamanaka
TST. Sakamoto
T. Sakamoto
YOY. Okita
Y. Okita